Advertisement

Cancer Chemotherapy by Infusion

  • Authors
  • Jacob J. Lokich

Table of contents

  1. Front Matter
    Pages i-xxvii
  2. Rationale and Technical Aspects

    1. Front Matter
      Pages 1-1
    2. Mark J. Ratain, Nicholas J. Vogelzang
      Pages 12-34
    3. Gregory A. Curt, Jerry M. Collins
      Pages 35-40
    4. Cheryl L. Moore
      Pages 74-99
    5. John A. Benvenuto, Stephen C. Adams, Harish M. Vyas, Roger W. Anderson
      Pages 100-113
  3. Chemotherapeutic Agents

    1. Front Matter
      Pages 115-115
    2. Carmen J. Allegra, Gregory A. Curt
      Pages 123-129
    3. Sewa S. Legha, Gabriel N. Hortobagyi, Robert S. Benjamin
      Pages 130-144
    4. Stephen P. Ackland, Nicholas J. Vogelzang
      Pages 145-160
    5. Gregory A. Curt, Carmen J. Allegra, Bruce D. Cheson
      Pages 161-166
    6. Mark J. Ratain, Nicholas J. Vogelzang, Gerald P. Bodey
      Pages 167-180
    7. Don V. Jackson Jr.
      Pages 181-199
    8. Robert B. Catalano, Robert L. Comis
      Pages 200-210
    9. Nancy Phillips, Robert L. Comis
      Pages 211-220
    10. Jacob J. Lokich
      Pages 221-230
    11. Merrill J. Egorin
      Pages 231-242
    12. Jacob J. Lokich
      Pages 243-262
  4. Systemic Infusion by Tumor Category

    1. Front Matter
      Pages 263-263
    2. Efstathios Tapazoglou, Muhyi Al-Sarraf
      Pages 265-280
    3. Lawrence Leichman, Jacob J. Lokich, Cynthia G. Leichman
      Pages 281-290
    4. Jacob J. Lokich
      Pages 291-303
    5. Geoffrey Falkson, Baruch Klein
      Pages 304-315
    6. Sewa S. Legha
      Pages 316-321
    7. Murray M. Bern
      Pages 322-337
    8. Lucien Israel, Jean-Luc Breau, Jean François Morere
      Pages 338-352
    9. Hyman B. Muss
      Pages 368-379
    10. Jacob J. Lokich, Richard Lackman, Arthur J. Weiss
      Pages 380-387
    11. Jacob J. Lokich
      Pages 388-395
  5. Regional Infusion

    1. Front Matter
      Pages 397-397
    2. Richard H. Wheeler, Shan R. Baker
      Pages 399-414
    3. Yeu-Tsu Margaret Lee
      Pages 415-434
    4. Alfred E. Chang, Philip D. Schneider, Paul H. Sugarbaker
      Pages 435-446
    5. Charles M. Balch, Marshall M. Urist
      Pages 447-454
    6. A. Gerard, J. C. Pector
      Pages 455-464
  6. Special Categories of Infusion Chemotherapy

    1. Front Matter
      Pages 465-465
    2. Fred H. Hochberg, Deborah O. Heros
      Pages 467-478
    3. Maurie Markman
      Pages 502-524
    4. Deborah O. Heros, Fred H. Hochberg
      Pages 525-537
    5. Hugh A. G. Fisher
      Pages 538-559
    6. Leif Håkansson, Hans Starkhammar, Stefan Ekberg, Olallo Morales, Rune Sjödahl, John Svedberg
      Pages 588-599
    7. Jacob J. Lokich
      Pages 600-612

About this book

Introduction

Chemotherapy for-cancer is in a state of evolution. Because some cancers can now be cured with chemotherapy as a singular modality, this therapy can no longer be viewed as simply a palliative contribution. Chemotherapy has assumed an important role as an adjuvant to other modalities, including both surgery and radiation therapy. For some tumors, the primary application of chemotherapy in a combined modality approach to curative therapy has resulted in the application of less radical surgery while achieving substantial of relatively rare tumors such as cure rates. Nonetheless, with the exception childhood tumors, hematologic malignancies, and testicular cancer, the effec­ tiveness of chemotherapy in most tumors is severely limited. At the cellular level, greater understanding of the specific mechanism of tumor cell killing and of the phenomenon of drug resistance are elusive, critical ingredients in the improvement of effectiveness in cancer chemotherapy. Prolonging the exposure time of the tumor cell to drugs is a concept that was addressed in the early phases of the development of chemotherapy. How­ ever, technological limitations inhibited the broader application of chemother­ apy by infusion until recent years. Also, the convenience of intermittent ther­ apy on an outpatient basis, with the predominant theory of drug effect based on a dose response as well as the proven effectiveness of this schedule in some tumors, has slowed the process of subjecting infusion chemotherapy to the rigors of clinical trials.

Keywords

Staging brain tumors carcinoma cell classification clinical trial esophagus liver liver tumor lymphoma melanoma metastasis ovarian cancer pharmacology tumor

Bibliographic information

  • DOI https://doi.org/10.1007/978-94-009-3193-0
  • Copyright Information Springer Science+Business Media B.V. 1987
  • Publisher Name Springer, Dordrecht
  • eBook Packages Springer Book Archive
  • Print ISBN 978-94-010-7932-7
  • Online ISBN 978-94-009-3193-0
  • Buy this book on publisher's site